Search the Newsreel

Brinker International, Inc. Stock 12‑Month Price Target Raised to $272, Implies 14% Upside

Brinker International, Inc. (EAT) has seen its average 12-month price target raised to $272 from $267.22, based on estimates from 18 analysts. This updated target suggests a potential upside of approximately 14% from its August 13 closing price. The consensus rating for EAT remains …

DYO BOYA FABRİKALARI SANAYİ VE TİCARET A.Ş.(DYOBY) Sorumluluk Beyanı (Konsolide) 13 Ağustos 2026

Seabridge Gold (NYSE: SA) gains $151.7M from spin-out, advances giant KSM project

Seabridge Gold reported strong financial results for the three and six months ended June 30, 2026, primarily due to a $151.7 million gain from the spin-out of its Courageous Lake Project into Valor Gold Corp. The company achieved a net income of $117.5 million …

Why Bri-Chem Corp. stock plummeted yesterday

iFabric Corp. (TSX:IFAB) Shares Slide as Market Reassesses Valuation, Growth Expectations and Short-Term Risks

Brinker International (NYSE:EAT) Rating Lowered to "Neutral" at Northcoast Research

Northcoast Research downgraded Brinker International (NYSE:EAT) from "buy" to "neutral" despite the stock trading near its 52-week high and a positive quarterly revenue report. The company reported $1.54 billion in revenue, exceeding expectations, though EPS slightly missed consensus. Despite this downgrade, analyst sentiment remains …

Rubrik CTO Arvind Nithrakashyap Sells $3.0 Million Stock

Key Points The transaction involved the sale of 38,460 shares at a weighted average price of $79.19, totaling ~$3 million. This disposition reduced the executive's direct stake in the company by ~12%. The sale was executed through the exercise of 38,460 stock options, with …

Analyst Estimates: Here's What Brokers Think Of BridgeBio Pharma, Inc. (NASDAQ:BBIO) After Its Second-Quarter Report

This article analyzes what brokers think of BridgeBio Pharma, Inc. (NASDAQ:BBIO) following its second-quarter report. It would likely detail analyst ratings, price targets, and any changes in sentiment post-earnings, providing insights into the company's financial performance and future outlook from an investment perspective.

Needham cuts Cellebrite stock price target on guidance reduction

Needham has lowered its price target for Cellebrite DI Ltd. (NASDAQ:CLBT) to $12.50 from $15.00, while maintaining a Buy rating. This adjustment follows Cellebrite's reduced fiscal 2026 guidance for annual recurring revenue and total revenue, alongside the appointment of Shiven Ramji as the new …

Fabrinet Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

British American Tobacco slides Friday, underperforms market

British American Tobacco PLC (BATS) shares fell 1.17% on Friday, closing at £42.14. This performance underperformed the broader market, as the FTSE 100 Index (UKX) saw a smaller decline of 0.21%. The company's stock is now 20.88% below its 52-week high.

iFabric Corp.’s Q2 Sales Vault 65 Percent

Die Bristol-Myers-Squibb-Aktie legt nach starken Q2-Zahlen und neuer Zahlung zu

BMS welcomes new multiple myeloma drug as generics batter current portfolio

Bristol Myers Squibb (BMS) received accelerated FDA approval for Zenbexus (iberdomide) for multiple myeloma, offering a new revenue stream as generics severely impact sales of its existing drugs, Revlimid and Pomalyst. Zenbexus is projected to achieve over $1 billion in annual earnings by 2031, …

China Everbright Water to Pay Interest on 2025 Medium-Term Notes After Interim Dividend

WaterBridge (WBI) Raised Guidance Again, So Why Did Shares Slip?

WaterBridge Infrastructure (NYSE:WBI) just posted record quarterly revenue, raised its full-year outlook for the second straight quarter, and closed a wave of acquisitions that doubled its waste management footprint in the Delaware Basin. Yet the stock fell 1.73% around the release. For a produced …

Future Bright Warns of Half-Year Loss as Catering Business Weakens

BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base

BridgeBio Pharma, Inc. announced the pricing of an oversubscribed secondary offering of 5,000,000 shares of its common stock by KKR Genetic Disorder L.P. The company itself is not selling shares and will not receive any proceeds from the offering. This transaction aims to further …

KKR to Sell 5M BridgeBio Shares; Company Receives No Proceeds

BridgeBio Pharma announced the pricing of a secondary offering of 5,000,000 shares of its common stock by existing shareholder KKR Genetic Disorder L.P. BridgeBio will not issue any shares or receive any proceeds from this transaction, which is expected to close on August 17, …

BridgeBio Pharma (BBIO) holders to resell 5M shares in $390M offering

BridgeBio Pharma is facilitating a secondary offering where a KKR-affiliated selling stockholder will sell 5,000,000 shares of common stock at $78.00 per share, totaling $390 million. BridgeBio Pharma will not receive any proceeds from this transaction, as all net proceeds will go to the …

Kolibri Global Energy Inc. Stock Surges 5.67% as Trading Activity Spikes and Market Attention Builds

Kolibri Global Energy Inc. (TSX:KEI) experienced a 5.67% stock surge on August 13, 2026, driven by a spike in trading activity, though the exact catalyst remains unverified. The company is an oil and natural gas producer focused on its Tishomingo field in Oklahoma. Investors …

Oxbridge Re earnings missed by $0.05, revenue fell short of estimates

QV Investors Inc. Sells 34,230 Shares of Enbridge Inc $ENB

QV Investors Inc. reduced its stake in Enbridge Inc. (NYSE:ENB) by 4.7% during the second quarter, selling 34,230 shares but still holding 696,095 shares valued at $37.7 million. Enbridge reported quarterly earnings of $0.46 per share, surpassing estimates, and declared a quarterly dividend of …

Oxley Bridge Acquisition (OBA) earns $4.3M on Trust but faces 2027 deadline

Oxley Bridge Acquisition Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Bristol Myers Squibb announces new $2.3bn campus in the US

Bristol Myers Squibb has announced a new $2.3 billion multi-modal manufacturing campus in Houston, Texas, creating nearly 500 skilled jobs. This investment is part of BMS's $40 billion commitment to the US, aiming to accelerate the delivery of next-generation medicines. The campus's modular design …

Corebridge Financial, Inc. $CRBG Shares Sold by Royal Bank of Canada

Exchange Traded Concepts LLC Sells 89,348 Shares of Enbridge Inc $ENB

Exchange Traded Concepts LLC reduced its stake in Enbridge Inc. by 7.2% in the second quarter, selling 89,348 shares and retaining 1.14 million shares valued at approximately $62 million. Enbridge reported strong quarterly results, beating analyst expectations for both EPS and revenue, and declared …

Does Cellebrite DI’s Lowered 2026 Outlook and New CEO Reset Its AI Narrative (CLBT)?

In August 2026, Cellebrite DI Ltd. reported second-quarter results showing revenue of US$131.14 million and net income of US$6.37 million, while lowering its full-year 2026 revenue guidance to US$555 million–US$561 million and announcing Shiven Ramji's appointment as CEO, succeeding Thomas E. Hogan. The combination …

BAER|Bridger Aerospace Group Holdings Inc|Price:1.245|Chg%:+0.045

British Land (LON:BLND) Stock Passes Above 200 Day Moving Average - Here's What Happened

GABRIEL Share Price Today - Gabriel India Stock Analysis

EAT|Brinker International Inc|Price:237.150|Chg%:-1.490

Brigade Enterprises Q1 Results: Unaudited financials for Q1FY26 published

Seabridge Gold Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

ETFs Investing in Cellebrite DI Ltd. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Cellebrite DI Ltd. (CLBT), providing detailed information such as market value, weight, issuer, management style, expense ratio, AUM, price change, relative volume, and 3-year NAV total return for each fund. It aims …